Summary
Previous reports have indicated abnormalities in the concentrations of metabolites of the tryptophan/kynurenine pathway in the brain in Huntington's disease. These have included an increase in 3-hydroxykynurenine and both increases and decreases in kynurenic acid. The activities of two enzymes involved in the metabolism of these compounds, 3-hydroxykynureninase and kynurenine aminotransferase, have been determined in post mortem brain tissue taken from Huntington's disease patients and control subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED (1990) Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55: 1327–1339
Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann Neurol 31: 119–130
Birch P, Grossman CJ, Hayes AG (1988) Kynurenate and FG9041 have both competitive and non-competitive actions at excitatory amino acid receptors. Eur J Pharmacol 151: 313–315
Connick JH, Carla V, Moroni F, Stone TW (1989) Increase in kynurenic acid in Huntington's disease cortex. J Neurochem 52: 985–987
De la Monte SM, Vonsattel JP, Richardson EP (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47: 516–525
Dure LS, Young AB, Penney JB (1991) Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann Neurol 30: 785–793
Eastman CL, Guilarte TR (1990) The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 15: 1101–1107
Heyes MP, Saito K, Crowley S, Davies LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJP, Lackner A, Larsen SA, Lee K, Leonard HL, Markey SP, Martin A, Milstein S, Mouradian MM, Pranzatelli MR, Quearry BJ, Salazar A, Smith M, Strauss SE, Sunderland T, Swedo SW, Tourtellotte WW (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115: 1249–1273
Inada J, Okuno E, Kimura M, Kido R (1984) Intracellular localisation and characterisation of 3-hydroxykynureninase in human liver. Int J Biochem 16: 623–628
Jahr CE, Jessel TM (1985) Synaptic transmission between dorsal root ganglion and dorsal horn neurons in culture: antagonism of monosynaptic excitatory post-synaptic potentials and glutamate excitation by kynurenate. J Neurosci 5: 2281–2289
Kawai J, Okuno E, Kido R (1988) Organ distribution of rat kynureninase and changes of its activity during development. Enzyme 39: 181–189
Lapin IP (1981) Kynurenines and seizures. Epilepsia 22: 257–265
Okuno E, Nakamura M, Schwarcz R (1991a) Two kynurenine aminotransferases in human brain. Brain Res 542: 307–312
Okuno E, Schmidt W, Parks DA, Nakamura M, Schwarcz R (1991b) Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J Neurochem 57: 533–554
Pearson SJ, Reynolds GP (1991) Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Increased concentrations in hepatic encephalopathy. J Chromatogr 565: 436–440
Pearson SJ, Reynolds GP (1992) Increased concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci Lett 144: 199–201
Reynolds GP (1985) Neurochemical studies in human postmortem brain tissue. In: Boulton AA, Baker GB (eds) General neurochemical techniques. Humana Press, New Jersey, pp 477–496
Reynolds GP, Pearson SJ, Halket J, Sandler M (1988) Brain quinolinic acid in Huntington's disease. J Neurochem 50: 1959–1960
Reynolds GP, Pearson SJ, Hutson PH (1994) Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease. J Neurol Sci 125: 46–49
Sardar AM, Bell JE, Reynolds GP (1995) Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1 positive patients. J Neurochem 64: 932–935
Sardar AM, Reynolds GP (1995) Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett 186: 1–4
Schwarcz R, Whetsell WO, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that causes axon-sparing lesions in rat brain. Science 219: 316–318
Stone TW (1993) Neuropharmacology of quinolinic acid and kynurenic acids. Pharmacol Rev 45: 309–379
Takeuchi F, Otsuka H, Shibata Y (1980) Purification and properties of kynureninase from rat liver. J Biochem 88: 987–984
Wasynczuk A, Kirksey A, Morre DM (1983) Effects of maternal vitamin B6 on specific regions of developing rat brain: the extrapyramidal motor system. J Nutr 113: 746–754
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pearson, S.J., Meldrum, A. & Reynolds, G.P. An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. J. Neural Transmission 102, 67–73 (1995). https://doi.org/10.1007/BF01276566
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01276566